國立虎尾科技大學 |

Polyglutamine Disorders

紀錄類型:	書目-語言資料,印刷品 : Monograph/item
正題名/作者:	Polyglutamine Disorders/ edited by Clévio Nóbrega, Luís Pereira de Almeida.
其他作者:	Nóbrega, Clévio.
面頁冊數:	VIII, 469 p. 41 illus., 39 illus. in color.online resource. :
Contained By:	Springer Nature eBook
標題:	Neurosciences. -
電子資源:	https://doi.org/10.1007/978-3-319-71779-1
ISBN:	9783319717791

Polyglutamine Disorders
Polyglutamine Disorders[electronic resource] /edited by Clévio Nóbrega, Luís Pereira de Almeida. - 1st ed. 2018. - VIII, 469 p. 41 illus., 39 illus. in color.online resource. - Advances in Experimental Medicine and Biology,10490065-2598 ;. - Advances in Experimental Medicine and Biology,889.

This book provides a cutting-edge review of polyglutamine disorders. It primarily focuses on two main aspects: (1) the mechanisms underlying the pathologies’ development and progression, and (2) the therapeutic strategies that are currently being explored to stop or delay disease progression. Polyglutamine (polyQ) disorders are a group of inherited neurodegenerative diseases with a fatal outcome that are caused by an abnormal expansion of a coding trinucleotide repeat (CAG), which is then translated in an abnormal protein with an elongated glutamine tract (Q). To date, nine polyQ disorders have been identified and described: dentatorubral-pallidoluysian atrophy (DRPLA); Huntington’s disease (HD); spinal–bulbar muscular atrophy (SBMA); and six spinocerebellar ataxias (SCA 1, 2, 3, 6, 7, and 17). The genetic basis of polyQ disorders is well established and described, and despite important advances that have opened up the possibility of generating genetic models of the disease, the mechanisms that cause neuronal degeneration are still largely unknown and there is currently no treatment available for these disorders. Further, it is believed that the different polyQ may share some mechanisms and pathways contributing to neurodegeneration and disease progression.

ISBN: 9783319717791

Standard No.: 10.1007/978-3-319-71779-1doiSubjects--Topical Terms:

593561
Neurosciences.

LC Class. No.: RC321-580

Dewey Class. No.: 612.8

Polyglutamine Disorders
LDR:02722nam a22003975i 4500 001 997766
003 DE-He213
005 20200630113225.0
007 cr nn 008mamaa
008 201225s2018 gw | s |||| 0|eng d
020 $a 9783319717791 $9 978-3-319-71779-1
024 7 $a 10.1007/978-3-319-71779-1 $2 doi
035 $a 978-3-319-71779-1
050 4 $a RC321-580
072 7 $a PSAN $2 bicssc
072 7 $a MED057000 $2 bisacsh
072 7 $a PSAN $2 thema
082 0 4 $a 612.8 $2 23
245 1 0 $a Polyglutamine Disorders $h [electronic resource] / $c edited by Clévio Nóbrega, Luís Pereira de Almeida.
250 $a 1st ed. 2018.
264 1 $a Cham : $b Springer International Publishing : $b Imprint: Springer, $c 2018.
300 $a VIII, 469 p. 41 illus., 39 illus. in color. $b online resource.
336 $a text $b txt $2 rdacontent
337 $a computer $b c $2 rdamedia
338 $a online resource $b cr $2 rdacarrier
347 $a text file $b PDF $2 rda
490 1 $a Advances in Experimental Medicine and Biology, $x 0065-2598 ; $v 1049
520 $a This book provides a cutting-edge review of polyglutamine disorders. It primarily focuses on two main aspects: (1) the mechanisms underlying the pathologies’ development and progression, and (2) the therapeutic strategies that are currently being explored to stop or delay disease progression. Polyglutamine (polyQ) disorders are a group of inherited neurodegenerative diseases with a fatal outcome that are caused by an abnormal expansion of a coding trinucleotide repeat (CAG), which is then translated in an abnormal protein with an elongated glutamine tract (Q). To date, nine polyQ disorders have been identified and described: dentatorubral-pallidoluysian atrophy (DRPLA); Huntington’s disease (HD); spinal–bulbar muscular atrophy (SBMA); and six spinocerebellar ataxias (SCA 1, 2, 3, 6, 7, and 17). The genetic basis of polyQ disorders is well established and described, and despite important advances that have opened up the possibility of generating genetic models of the disease, the mechanisms that cause neuronal degeneration are still largely unknown and there is currently no treatment available for these disorders. Further, it is believed that the different polyQ may share some mechanisms and pathways contributing to neurodegeneration and disease progression.
650 0 $a Neurosciences. $3 593561
650 0 $a Neurology . $3 1253459
650 0 $a Medical genetics. $3 678508
650 2 4 $a Neurology. $3 593894
650 2 4 $a Gene Function. $3 782134
700 1 $a Nóbrega, Clévio. $e editor. $4 edt $4 http://id.loc.gov/vocabulary/relators/edt $3 1289155
700 1 $a Pereira de Almeida, Luís. $e editor. $4 edt $4 http://id.loc.gov/vocabulary/relators/edt $3 1289156
710 2 $a SpringerLink (Online service) $3 593884
773 0 $t Springer Nature eBook
776 0 8 $i Printed edition: $z 9783319717784
776 0 8 $i Printed edition: $z 9783319717807
776 0 8 $i Printed edition: $z 9783319891033
830 0 $a Advances in Experimental Medicine and Biology, $x 0065-2598 ; $v 889 $3 1253792
856 4 0 $u https://doi.org/10.1007/978-3-319-71779-1
912 $a ZDB-2-SBL
912 $a ZDB-2-SXB
950 $a Biomedical and Life Sciences (SpringerNature-11642)
950 $a Biomedical and Life Sciences (R0) (SpringerNature-43708)